NYSE: OGNOrganon & Co Stock
$13.60+0.05 (+0.37%)
Updated Aug 7, 2026
OGN Price
$13.60
Fair Value Price
N/A
Market Cap
$3.57B
52 Week Low
$5.69
52 Week High
$13.61
P/E
17.22x
P/B
3.55x
P/S
0.58x
PEG
0.24x
Dividend Yield
0.59%
Revenue
$6.13B
Earnings
$209.00M
Gross Margin
52.7%
Operating Margin
15.65%
Profit Margin
3.4%
Debt to Equity
12.1
Operating Cash Flow
$737M
Beta
0.8
Next Earnings
N/A
Ex-Dividend
Aug 14, 2026
Next Dividend
Sep 10, 2026
OGN Overview
Organon & Co. offers prescription drugs in the U.S. and internationally. Its Women's Health portfolio includes contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. Its Biosimilars portfolio consists immunology products (Brenzys, Renflexis, and Hadlima), as well as oncology products (Ontruzant and Aybintio). The company also offers cholesterol-modifying cardiovascular products (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor). Organon & Co. was incorporated in 2020 and is headquartered in Jersey City, NJ.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OGN's potential to beat the market
- OGN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: General Drug Manufacturer
Industry Rating
A
OGN
RankedUnranked of 16
RankedUnranked of 16
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $64.72 | A | |
| $1,185.71 | B | |
| $246.04 | B |
Be the first to know about important OGN news, forecast changes, insider trades & much more!
OGN News
Overview
Due Diligence Score
–
Industry Average (35)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OGN scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OGN ($13.60) is trading below its intrinsic value of $22.08, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OGN is poor value based on its earnings relative to its share price (17.22x), compared to the US market average (13.41x)
P/E vs Market Valuation
OGN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more OGN due diligence checks available for Premium users.
Valuation
OGN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
17.22x
Industry
32.11x
Market
13.41x
OGN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
OGN is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
OGN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.55x
Industry
7.77x
OGN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OGN price to earnings growth (PEG)
For valuing profitable companies with growth potential
OGN is good value based... subscribe to Premium to read more.
PEG Value Valuation
OGN's financial health
Profit margin
Revenue
$1.6B
Net Income
$108.0M
Profit Margin
6.9%
OGN's Earnings (EBIT) of $959.00M... subscribe to Premium to read more.
Interest Coverage Financials
OGN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$13.2B
Liabilities
$12.2B
Debt to equity
12.1
OGN's short-term assets ($5.11B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OGN's long-term liabilities ($9.56B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OGN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$107.0M
Investing
-$76.0M
Financing
-$12.0M
OGN's operating cash flow ($737.00M)... subscribe to Premium to read more.
Debt Coverage Financials
OGN vs General Drug Manufacturer Stocks
Organon & Co Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.